| 16 to 18-hour infusions of eptifibatide seem optimal in reducing ischemic complications following percutaneous coronary intervention AG Rebeiz, KS Pieper, JC O'Shea, IC Gilchrist, B Chandler, J Slater, ... Circulation 104 (17), 386-386, 2001 | | 2001 |
| A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis (vol 39, pg 1102, 1996) NJ Olsen, RH Brooks, JJ Cush, PE Lipsky, EW StClair, EL Matteson, ... ARTHRITIS AND RHEUMATISM 39 (9), 1575-1575, 1996 | 1 | 1996 |
| A double‐blind, placebo‐controlled study of anti‐CD5 immunoconjugate in patients with rheumatoid arthritis NJ Olsen, RH Brooks, JJ Cush, PE Lipsky, EW St. Clair, EL Matteson, ... Arthritis & Rheumatism: Official Journal of the American College of …, 1996 | 66 | 1996 |
| A phase 2 randomized, double-blind, placebo-controlled trial of PRT064445, a novel, universal antidote for direct and indirect factor Xa inhibitors M Crowther, M Kitt, T Lorenz, V Mathur, G Lu, A Hutchaleelaha, ... J Thromb Haemost 11 (suppl 2), 30, 2013 | 94 | 2013 |
| A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer HKM Vollan, OM Rueda, SF Chin, C Curtis, G Turashvili, S Shah, ... Molecular oncology 9 (1), 115-127, 2015 | 52 | 2015 |
| Acromegaly with'normal'growth hormone levels. KR Feingold, TJ Lorenz Western Journal of Medicine 142 (1), 95, 1985 | 4 | 1985 |
| Bailout platelet GP IIb/IIIa inhibition in coronary stent implantation: Observations from the ESPRIT trial WJ Cantor, AS Hellkamp, JC O'Shea, M Madan, RJ Chisholm, TJ Lorenz, ... JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 37 (2), 84A-84A, 2001 | 1 | 2001 |
| CD5 Diabetes Project Team: Effects of an anti-CD5 immunoconjugate (CD5-Plus™) in recent onset type I diabetes mellitus—a preliminary investigation JS Skyler, TJ Lorenz, S Schwartz, GS Eisenbarth, D Einhorn, JP Palmer, ... J Diabetes Complications 7, 224-232, 1993 | 3 | 1993 |
| Clinical Investigation and Reports-Early Percutaneous Coronary Intervention, Platelet Inhibition With Eptifibatide, and Clinical Outcomes in Patients With Acute Coronary Syndromes NS Kleiman, AM Lincoff, GC Flaker, KS Pieper, RG Wilcox, LG Berdan, ... Circulation 101 (7), 751-757, 2000 | 6 | 2000 |
| Clinical Investigation and Reports-Pharmacodynamics and Pharmacokinetics of Higher-Dose, Double-Bolus Eptifibatide in Percutaneous Coronary Intervention IC Gilchrist, JC O'Shea, T Kosoglou, LK Jennings, TJ Lorenz, MM Kitt, ... Circulation-Hagertown 104 (4), 406-411, 2001 | | 2001 |
| Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study) JE Tcheng, JD Talley, JC O’Shea, IC Gilchrist, NS Kleiman, CL Grines, ... The American journal of cardiology 88 (10), 1097-1102, 2001 | 86 | 2001 |
| Combined therapy with streptokinase and integrilin E Ronner, HAM van Kesteren, P Zijnen, U Tebbe, P Molhoek, C Cuffie, ... Journal of the American College of Cardiology 31 (2SA), 191A-191A, 1998 | 52 | 1998 |
| Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention JC O’Shea, M Madan, WJ Cantor, CM Pacchiana, S Greenberg, ... American Heart Journal 140 (6), 834-839, 2000 | 46 | 2000 |
| Design and rationale of the PREVENT III clinical trial: edifoligide for the prevention of infrainguinal vein graft failure MS Conte, TJ Lorenz, DF Bandyk, AW Clowes, GL Moneta, BL Seely Vascular and endovascular surgery 39 (1), 15-23, 2005 | 61 | 2005 |
| Differential effects of citrate versus PPACK anticoagulants: Implications for comparing glycoprotein IIb/IIIa inhibitors. GL Kukielka, DJ Kereiakes, T Lorenz, MN Mueller, D Andrade, N Halsey, ... AMERICAN JOURNAL OF CARDIOLOGY 86 (8 A), 69I-70I, 2000 | 6 | 2000 |
| Differential effects of citrate versus PPACK anticoagulation on measured platelet inhibition by abciximab, eptifibatide and tirofiban DJ Kereiakes, T Lorenz, JJ Young, G Kukielka, MN Mueller, ... Journal of thrombosis and thrombolysis 12, 123-127, 2001 | 33 | 2001 |
| Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes NS Kleiman, AM Lincoff, GC Flaker, KS Pieper, RG Wilcox, LG Berdan, ... Circulation 101 (7), 751-757, 2000 | 149 | 2000 |
| Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results RD Lopes, JB Williams, RH Mehta, EM Reyes, GE Hafley, KB Allen, ... American heart journal 164 (3), 379-386. e1, 2012 | 49 | 2012 |
| Effect of eptifibatide on coronary flow reserve following coronary stent implantation (an ESPRIT substudy) CM Gibson, DJ Cohen, EA Cohen, HK Lui, SA Murphy, SJ Marble, M Kitt, ... American Journal of Cardiology 87 (11), 1293-1295, 2001 | 45 | 2001 |
| Effect of glycoprotein IIb/IIIa receptor inhibition on in-lab adverse events and subsequent CK-MB elevation during percutaneous coronary intervention in ESPRIT FA Bachour, JC Blankenship, EA Iliadis, G Tasissa, JC O'Shea, MM Kitt, ... JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 37 (2), 84A-84A, 2001 | 1 | 2001 |
